Search for: "ASTRAZENECA LP" Results 121 - 140 of 161
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Oct 2013, 3:56 am by Lorene Park
In the court’s view, this circumstantial evidence of a “pattern of antagonism” raised an inference of retaliation and was enough to support her Title VII claim (Brangman v AstraZeneca, LP). [read post]
16 May 2012, 12:22 pm by Bexis
AstraZeneca Pharmaceuticals, LP, 634 F.3d 1352, 1360-66 (11th Cir. 2011) (plaintiff had not pleaded recoverable economic injury); Polk v. [read post]
17 Dec 2015, 11:54 am by Dennis Crouch
  Patents in his portfolio include US Patent Numbers 6,331,400, 6,771,291, 7,353,199, 7,996,259, 8,335,713, 8,412,570, 8,417,567, 8,423,399, 8,442,860, 8,589,222, 8,650,076, 8,768,760, 8,781,890 and 8,996,398.[8] = = = = = [1] US patent Application No. 10/868,312, claim number 24. [2] See 1 Chisum on Patents section 1.02. [3] In re Russell, 48 F.2d 668, 669 (CCPA 1931)(indexing the names in directories and dictionaries). [4] AstraZeneca LP v. [read post]
13 Nov 2014, 5:00 am
Courtesy of Mike Imbroscio of Covington (who was on the winning team) today’s post is about a very satisfying Cymbalta win – not only did warning causation fail under the learned intermediary rule, but the warning for the drug was held adequate as a matter of law. [read post]
14 Aug 2013, 1:57 pm
We’ve already provided our readers with our list of the testimony (trial and deposition) of the seemingly ubiquitous plaintiff’s expert Dr. [read post]
15 Jun 2012, 12:19 pm by Schachtman
AstraZeneca LP, 2009 WL 1610575 at 8 (Del. [read post]
24 Sep 2010, 7:00 am by Kara OBrien
Goldfield, Civil Action No. 10-CV-4430-ER (E.D.P.A.): In this case, the SEC alleges that Self, an Executive Director of Business Development at a pharmaceutical company and Goldfield, a former hedge fund manager, engaged in unlawful insider trading in advance of the April 23, 2007 announcement that AstraZeneca would acquire MedImmune, Inc. [read post]